Pinnacle Bancorp Inc. Cuts Stock Position in Sanofi (NASDAQ:SNY)

Pinnacle Bancorp Inc. trimmed its stake in shares of Sanofi (NASDAQ:SNY) by 18.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,006 shares of the company’s stock after selling 221 shares during the quarter. Pinnacle Bancorp Inc.’s holdings in Sanofi were worth $49,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Victory Capital Management Inc. boosted its stake in shares of Sanofi by 11.9% in the second quarter. Victory Capital Management Inc. now owns 6,793 shares of the company’s stock worth $330,000 after acquiring an additional 722 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Sanofi by 8.4% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 141,159 shares of the company’s stock valued at $6,849,000 after purchasing an additional 10,941 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Sanofi by 0.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 318,760 shares of the company’s stock worth $15,466,000 after purchasing an additional 1,238 shares during the last quarter. Moors & Cabot Inc. grew its holdings in shares of Sanofi by 14.1% during the second quarter. Moors & Cabot Inc. now owns 8,288 shares of the company’s stock worth $402,000 after buying an additional 1,026 shares in the last quarter. Finally, Argent Trust Co raised its position in shares of Sanofi by 11.7% in the second quarter. Argent Trust Co now owns 23,594 shares of the company’s stock valued at $1,145,000 after buying an additional 2,478 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Stock Performance

NASDAQ SNY opened at $50.70 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The stock’s fifty day moving average is $48.49 and its two-hundred day moving average is $52.09. The firm has a market capitalization of $128.66 billion, a P/E ratio of 25.86, a price-to-earnings-growth ratio of 1.17 and a beta of 0.57. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter in the previous year, the company posted $2.55 EPS. The company’s revenue was up 12.3% compared to the same quarter last year. On average, research analysts anticipate that Sanofi will post 3.94 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.